21-hydroxylase deficiency screening: Difference between revisions

Jump to navigation Jump to search
Line 9: Line 9:
According to the the Endocrine Society’s CGS and Clinical Affairs Core Committee, screening for [[congenital adrenal hyperplasia]] due to 21-hydroxylase deficiency by determining the serum level of [[17-hydroxyprogesterone|17OHP]], androstenedione, and [[cortisol]] is recommended in [[newborns]].<ref name="Wikipeadia">https://en.wikipedia.org/wiki/Congenital_adrenal_hyperplasia_due_to_21-hydroxylase_deficiency#Newborn_screening</ref><ref name="pmid19390483">{{cite journal| author=Schwarz E, Liu A, Randall H, Haslip C, Keune F, Murray M et al.| title=Use of steroid profiling by UPLC-MS/MS as a second tier test in newborn screening for congenital adrenal hyperplasia: the Utah experience. | journal=Pediatr Res | year= 2009 | volume= 66 | issue= 2 | pages= 230-5 | pmid=19390483 | doi=10.1203/PDR.0b013e3181aa3777 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19390483  }}</ref>
According to the the Endocrine Society’s CGS and Clinical Affairs Core Committee, screening for [[congenital adrenal hyperplasia]] due to 21-hydroxylase deficiency by determining the serum level of [[17-hydroxyprogesterone|17OHP]], androstenedione, and [[cortisol]] is recommended in [[newborns]].<ref name="Wikipeadia">https://en.wikipedia.org/wiki/Congenital_adrenal_hyperplasia_due_to_21-hydroxylase_deficiency#Newborn_screening</ref><ref name="pmid19390483">{{cite journal| author=Schwarz E, Liu A, Randall H, Haslip C, Keune F, Murray M et al.| title=Use of steroid profiling by UPLC-MS/MS as a second tier test in newborn screening for congenital adrenal hyperplasia: the Utah experience. | journal=Pediatr Res | year= 2009 | volume= 66 | issue= 2 | pages= 230-5 | pmid=19390483 | doi=10.1203/PDR.0b013e3181aa3777 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19390483  }}</ref>
===Newborn screening===
===Newborn screening===
*In the last decade more states and countries are adopting newborn screening for salt-wasting [[congenital adrenal hyperplasia]] due to 21-hydroxylase deficiency, which leads to death in the first month of life, if not recognized.
*In the last decade more states and countries are adopting newborn screening for salt-wasting [[congenital adrenal hyperplasia]] due to 21-hydroxylase deficiency, which leads to death in the first month of life if not recognized.


*The [[17-hydroxyprogesterone|17OHP]] level is easy to measure and sensitive (rarely missing real cases), but has a poor specificity.
*The [[17-hydroxyprogesterone|17OHP]] level is easy to measure and sensitive (rarely missing real cases), but has a poor specificity.

Revision as of 18:42, 15 October 2015

Congenital adrenal hyperplasia due to 21-hydroxylase deficiency Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Congenital adrenal hyperplasia due to 21-hydroxylase deficiency from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

21-hydroxylase deficiency screening On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of 21-hydroxylase deficiency screening

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on 21-hydroxylase deficiency screening

CDC on 21-hydroxylase deficiency screening

21-hydroxylase deficiency screening in the news

Blogs on 21-hydroxylase deficiency screening

Directions to Hospitals Treating Congenital adrenal hyperplasia due to 21-hydroxylase deficiency

Risk calculators and risk factors for 21-hydroxylase deficiency screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Ahmad Al Maradni, M.D. [2]

Overview

According to the the Endocrine Society’s CGS and Clinical Affairs Core Committee, screening for congenital adrenal hyperplasia due to 21-hydroxylase deficiency by determining the serum level of 17OHP, androstenedione, and cortisol is recommended in newborns.[1][2]

Screening

According to the the Endocrine Society’s CGS and Clinical Affairs Core Committee, screening for congenital adrenal hyperplasia due to 21-hydroxylase deficiency by determining the serum level of 17OHP, androstenedione, and cortisol is recommended in newborns.[1][2]

Newborn screening

  • In the last decade more states and countries are adopting newborn screening for salt-wasting congenital adrenal hyperplasia due to 21-hydroxylase deficiency, which leads to death in the first month of life if not recognized.
  • The 17OHP level is easy to measure and sensitive (rarely missing real cases), but has a poor specificity.
  • Screening programs in the United States have reported that 99% of positive screens turn out to be false positives upon investigation of the infant. This is the highest rate of false positives cases among the screening tests for many other congenital metabolic diseases.
  • When a positive result is detected, the infant's family and doctor must be notified, and the infant must be referred to a pediatric endocrinologist to confirm or disprove the diagnosis.
  • Since most infants with salt-wasting congenital adrenal hyperplasia become critically ill by 2 weeks of age, the evaluation must be done rapidly despite and the screening for elevated 17OHP should be done even if there is a high false positive rate.[1][2]

Genetic counseling

  • If a family history of congenital adrenal hyperplasia due to 21-hydroxylase deficiency is present, genetic counseling is recommended for individuals who are planning to conceive.

References

  1. 1.0 1.1 1.2 https://en.wikipedia.org/wiki/Congenital_adrenal_hyperplasia_due_to_21-hydroxylase_deficiency#Newborn_screening
  2. 2.0 2.1 2.2 Schwarz E, Liu A, Randall H, Haslip C, Keune F, Murray M; et al. (2009). "Use of steroid profiling by UPLC-MS/MS as a second tier test in newborn screening for congenital adrenal hyperplasia: the Utah experience". Pediatr Res. 66 (2): 230–5. doi:10.1203/PDR.0b013e3181aa3777. PMID 19390483.

Template:WikiDoc Sources